Screener
Nurix Therapeutics, Inc. NRIX Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Nurix Therapeutics, Inc.’s 10-Q, filed July 9, 2026.
- Filed
- Jul 9, 2026, 4:12 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001549595-26-000040
| Line item | Six Months Ended May 31, 2026 | Six Months Ended May 31, 2025 |
|---|---|---|
| Net loss | $(176,709) | $(99,815) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 4,451 | 4,592 |
| Stock-based compensation | 20,792 | 19,107 |
| Net accretion of discount on marketable securities | (3,535) | (6,258) |
| Loss on disposal of property and equipment | 160 | — |
| Amortization of operating lease right-of-use assets | 3,175 | 4,633 |
| Changes in operating assets and liabilities: |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Nurix Therapeutics, Inc.'s stock-based comp?
- Nurix Therapeutics, Inc. (NRIX) reported stock-based comp of $11.39M in Q1 2026.
- How has Nurix Therapeutics, Inc.'s stock-based comp changed year-over-year?
- Nurix Therapeutics, Inc.'s stock-based comp increased by 9.7% year-over-year, from $10.39M to $11.39M.
- What is the long-term trend for Nurix Therapeutics, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Nurix Therapeutics, Inc.'s stock-based comp has grown at a 24.5% compound annual growth rate (CAGR), from $15.8M to $37.97M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Nurix Therapeutics, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude